Mr. Ron Nagar reports

TEMPRAMED GRANTED MEXICAN PATENT FOR NEWEST PRODUCT, VIVI BOX

Tempramed Technologies Ltd.'s Mexican patent application No. MX/a/2021/004595 has now been formally granted by the Mexican Patent Office.

Highlights:

• Covers core innovations underpinning Tempramed's Vivi Box multimedication storage platform;
• Strengthens the company's intellectual property position in one of the world's largest health care and consumer markets;
• Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector;
• Patent term extends through Oct. 24, 2039.

The patent includes claims covering key aspects of the company's first-of-its-kind, multimedication storage box, Vivi Box. Once launched, it will add to the existing portfolio of four products being sold in market. There are also many commercial application opportunities with the Vivi Box that the company has started exploring.

Without limiting the scope of the patent, it includes core elements of Tempramed's proprietary thermal-insulation and smart-monitoring architecture, such as:

• Continuous temperature protection during power interruptions or refrigerator temperature fluctuations for several medication devices and vials;
• Portable, all-day travel functionality for secure on-the-go cold storage;
• Smart content tracking with cloud-based data integration, supporting adherence and remote monitoring.

These capabilities position Vivi Box as a differentiated platform at the intersection of home health, smart refrigeration and the connected medical device ecosystem. The innovation supports Tempramed's strategy to expand beyond single-injection protection into scalable, multidose and multiformat medication storage systems -- an important pillar of the company's long-term commercialization road map.

"The formal grant of our Mexican patent represents a significant milestone in Tempramed's global intellectual property strategy," said Ron Nagar, chief executive officer of Tempramed. "Mexico is an important Latin American market for medical devices and health care technology, supported by an established medical device industry. Securing patent protection in this jurisdiction meaningfully strengthens our position and expands our presence comprehensive product portfolio across America.

"The Vivi Box will add to our existing portfolio of products we already have on the market, with our proprietary technology at the core of all of them. As we continue to build out new product categories and scale our platform, protecting our core innovations remains fundamental to unlocking long-term shareholder value and establishing global leadership in temperature-controlled medication management," commented Mr. Nagar.

This new grant follows a series of recent milestones for Tempramed, including grant of a similar patent in South Korea and China, entering into several distribution agreements, and validation of its return-on-investment (ROI) model for insurance payers as verified by hundreds of clinicians recommending Tempramed's Vivi Cap to patients.

Together, these achievements support the company's multiyear strategy to scale globally, introduce new product categories, and establish Tempramed as one of the worldwide leaders in temperature-regulated medication protection and management.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration) thermal-insulation devices that work 24 hours a day, seven days a week without batteries or external power. With a product line already in market, including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed will continue to expand globally, offering a solution for medication protection and adherence.

We seek Safe Harbor.